Open House Original Discount Contracts 2026-02 - Ponatinib

This tender concerns the establishment of pharmaceutical discount contracts for the drug Ponatinib, in accordance with Section 130c, Paragraph 1 of the German Social Code Book V (SGB V). The procurement process will follow an "Open House" procedure, which allows for continuous submission of bids. The primary objective is to secure favorable pricing and supply agreements for Ponatinib, a medication used in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

The "Open House" model implies that eligible pharmaceutical manufacturers or their authorized representatives can submit bids at any time during the contract period, provided they meet the specified criteria. This approach aims to foster competition and ensure access to essential medicines at competitive rates. The contracts are intended to be effective from 2026 onwards, with the reference "2026-02" likely indicating a specific batch or phase of the contracting process. Key requirements for bidders will likely include demonstrating the ability to supply the specified drug consistently, meeting quality standards, and offering a discount that aligns with the objectives of the German healthcare system. Further details regarding specific quantities, delivery terms, and evaluation criteria are expected to be outlined in the full tender documentation. This initiative is crucial for managing healthcare costs while ensuring patient access to necessary treatments within the German statutory health insurance framework.